Quest reported 10% revenue growth and raised its full-year revenue and EPS guidance; with the stock up 1.8%, the reaction was modest rather than a clear endorsement. The transcript cites broad channel growth and productivity gains, though the excerpt does not provide the revised guidance figures.
The 8.6% stock gain reflects investor approval of Quest Diagnostics’ broad-based revenue growth and strong adjusted EPS increase, supported by robust demand across clinical, hospital, and consumer segments and raised full-year guidance.
Quest Diagnostics delivered a robust first quarter with over 9% organic revenue growth and a 13% increase in adjusted EPS, driven by broad-based demand and operational efficiencies.